Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Frédéric Dhermain
Based on 5 articles published since 2008
||||

Between 2008 and 2019, F. Dhermain wrote the following 5 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline [ANOCEF guidelines for the management of brain metastases]. 2015

Le Rhun, É / Dhermain, F / Noël, G / Reyns, N / Carpentier, A / Mandonnet, E / Taillibert, S / Metellus, P / Anonymous2980820. ·Neuro-oncologie, département de neurochirurgie, hôpital Roger-Salengro, CHRU de Lille, rue Émile-Laine, 59037 Lille cedex, France; Oncologie médicale, centre Oscar-Lambret, 3, rue Frédéric-Combemale, BP 307, 59020 Lille cedex, France; Laboratoire Prism, université Lille 1, Inserm U1192, bâtiment SN3 1(er) étage, 59655 Villeneuve d'Ascq cedex, France; Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC) , 13273 Marseille cedex 09, France. Electronic address: emilie.lerhun@chru-lille.fr. · Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC) , 13273 Marseille cedex 09, France; Département de radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France; Réunion de concertation pluridisciplinaire de neuro-oncologie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France. · Département universitaire de radiothérapie, centre de lutte contre le cancer Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France; Laboratoire EA 3430, fédération de médecine translationnelle de Strasbourg (FMTS), université de Strasbourg, 4, rue Kirschleger, 67085 Strasbourg cedex, France. · Département de neurochirurgie, hôpital Roger-Salengro, CHRU de Lille, rue Émile-Laine, 59037 Lille cedex, France. · Service de neurologie, hôpital Avicenne, Assistance publique-Hôpitaux de Paris (AP-HP), 125, rue de Stalingrad, 93009 Bobigny cedex, France. · Département de neurochirurgie, hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris, France. · Département de neurologie 2, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Département de radiothérapie, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Université Pierre-et-Marie-Curie Paris VI, 4, place Jussieu, 75005 Paris, France. · Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC) , 13273 Marseille cedex 09, France; Département de neurochirurgie, centre hospitalo-universitaire La Timone, AP-HM, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France; Centre de recherche en oncologie et oncopharmacologie (CRO2), faculté de médecine Timone, université Aix-Marseille, 27, boulevard Jean-Moulin, 13385 Marseille cedex 05, France; Inserm U911, faculté de médecine Timone, 27, boulevard Jean-Moulin, 13385 Marseille cedex 05, France. ·Cancer Radiother · Pubmed #25666314.

ABSTRACT: The incidence of brain metastases is increasing because of the use of new therapeutic agents, which allow an improvement of overall survival, but with only a poor penetration into the central nervous system brain barriers. The management of brain metastases has changed due to a better knowledge of immunohistochemical data and molecular biological data, the development of new surgical, radiotherapeutic approaches and improvement of systemic treatments. Most of the time, the prognosis is still limited to several months, nevertheless, prolonged survival may be now observed in some sub-groups of patients. The main prognostic factors include the type and subtype of the primitive, age, general status of the patient, number and location of brain metastases, extracerebral disease. The multidisciplinary discussion should take into account all of these parameters. We should notice also that treatments including surgery or radiotherapy may be proposed in a symptomatic goal in advanced phases of the disease underlying the multidisciplinary approach until late in the evolution of the disease. This article reports on the ANOCEF (French neuro-oncology association) guidelines. The management of brain metastases of breast cancers and lung cancers are discussed in the same chapter, while the management of melanoma brain metastases is reported in a separate chapter due to different responses to the brain radiotherapy.

2 Editorial Stereotactic radiation and checkpoint inhibitors in melanoma patients with BM: a question of drug, timing or both? 2016

Dhermain, F / Deutsch, E. ·Department of Radiation Oncology and DITEP, Gustave Roussy, University Hospital, Université Paris-Saclay, INSERM 1030 Molecular Radiotherapy, Villejuif, France frederic.dhermain@gustaveroussy.fr. · Department of Radiation Oncology and DITEP, Gustave Roussy, University Hospital, Université Paris-Saclay, INSERM 1030 Molecular Radiotherapy, Villejuif, France. ·Ann Oncol · Pubmed #26782954.

ABSTRACT: -- No abstract --

3 Review [Systemic treatment of melanoma brain metastases]. 2015

Le Rhun, É / Mateus, C / Mortier, L / Dhermain, F / Guillot, B / Grob, J-J / Lebbe, C / Thomas, M / Jouary, T / Leccia, M-T / Robert, C. ·Neuro-oncologie, département de neurochirurgie, hôpital Roger-Salengro, CHRU, rue Émile-Laine, 59037 Lille cedex, France; Oncologie médicale, centre Oscar-Lambret, 3, rue Frédéric-Combemale, BP 307, 59020 Lille cedex, France; Inserm U1192, laboratoire Prism, université Lille 1, bâtiment SN3 1(er) étage, 59655 Villeneuve-d'Ascq cedex, France; Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC), 13273 Marseille cedex 09, France. Electronic address: emilie.lerhun@chru-lille.fr. · Département de dermatologie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France. · Département de dermatologie, centre hospitalier régional et universitaire de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France. · Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC), 13273 Marseille cedex 09, France; Département de radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France; Réunion de concertation pluridisciplinaire de neuro-oncologie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France. · Département de dermatologie, centre hospitalier universitaire, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France; Université Montpellier 1, 5, boulevard Henri-IV, CS 19044, 34967 Montpellier cedex 2, France. · Département de dermatologie, centre hospitalo-universitaire, AP-HM, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France. · Département de dermatologie, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France. · Service de dermatologie, pôle d'oncologie-radiothérapie, de dermatologie et des soins palliatifs, groupe hospitalier Saint-André, centre hospitalier universitaire de Bordeaux, 1, rue Jean-Burguet, 33075 Bordeaux, France. · Clinique de dermatologie, d'allergologie et de photobiologie, centre hospitalier Albert-Michallon, boulevard de la Chantourne, BP 217, 38043 Grenoble cedex 9, France; Inserm U832, institut A.-Bonniot, 38043 Grenoble cedex 09, France. ·Cancer Radiother · Pubmed #25656856.

ABSTRACT: Melanomas have a high rate of brain metastases. Both the functional prognosis and the overall survival are poor in these patients. Until now, surgery and radiotherapy represented the two main modalities of treatment. Nevertheless, due to the improvement in the management of the extracerebral melanoma, the systemic treatment may be an option in patients with brain metastases. Immunotherapy with anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) - ipilimumab - or BRAF (serine/threonine-protein kinase B-raf) inhibitors - vemurafenib, dabrafenib - has shown efficacy in the management of brain metastases in a- or pauci-symptomatic patients. Studies are ongoing with anti-PD1 (programmed cell death 1) and combinations of targeted therapies associating anti-RAF (raf proto-oncogene, serine/threonine kinase) and anti-MEK (mitogen-activated protein kinase kinase).

4 Review [Brain metastases imaging]. 2015

Delmaire, C / Savatovsky, J / Boulanger, T / Dhermain, F / Le Rhun, E / Météllus, P / Gerber, S / Carsin-Nicole, B / Petyt, G. ·Service de neuroradiologie, hôpital Roger-Salengro, CHRU de Lille, rue Émile-Laine, 59037 Lille cedex, France. · Service de neuroradiologie, fondation Rothschild, 78, rue de Picpus, 75012 Paris, France. · Service de radiologie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, BP 307, 59020 Lille cedex, France. · Service de radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France. · Neuro-oncologie, département de neurochirurgie, hôpital Roger-Salengro, CHRU de Lille, rue Émile-Laine, 59037 Lille cedex, France; Oncologie médicale, centre Oscar-Lambret, 3, rue Frédéric-Combemale, BP 307, 59020 Lille cedex, France; Laboratoire Prism, université Lille 1, bâtiment SN3 1(er) étage, 59655 Villeneuve-d'Ascq cedex, France; Inserm U1192, 59655 Villeneuve-d'Ascq cedex, France; Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC), 13273 Marseille cedex 09, France. · Groupe de réflexion sur la prise en charge des métastases cérébrales (GRPCMaC), 13273 Marseille cedex 09, France; Département de neurochirurgie, CHU La Timone, AP-HM, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France; Centre de recherche en oncologie et oncopharmacologie (CRO2), faculté de médecine Timone, université Aix-Marseille, 27, boulevard Jean-Moulin, 13385 Marseille cedex 05, France; Inserm U911, faculté de médecine Timone, 27, boulevard Jean-Moulin, 13385 Marseille cedex 05, France. Electronic address: philippe.metellus@mail.ap-hm.fr. · Service de neuroradiologie, hôpital Saint-Joseph, 185, rue Raymond-Losserand, 75674 Paris cedex 14, France. · Service de neuroradiologie, CHU de Rennes, 2, rue Henri-Le Guilloux, 35033 Rennes cedex 9, France. · Service de médecine nucléaire, centre Oscar-Lambret, CHRU de Lille, 3, rue Frédéric-Combemale, BP 307, 59020 Lille cedex, France. ·Cancer Radiother · Pubmed #25649387.

ABSTRACT: The therapeutic management of brain metastases depends upon their diagnosis and characteristics. It is therefore imperative that imaging provides accurate diagnosis, identification, size and localization information of intracranial lesions in patients with presumed cerebral metastatic disease. MRI exhibits superior sensitivity to CT for small lesions identification and to evaluate their precise anatomical location. The CT-scan will be made only in case of MRI's contraindication or if MRI cannot be obtained in an acceptable delay for the management of the patient. In clinical practice, the radiologic metastasis evaluation is based on visual image analyses. Thus, a particular attention is paid to the imaging protocol with the aim to optimize the diagnosis of small lesions and to evaluate their evolution. The MRI protocol must include: 1) non-contrast T1, 2) diffusion, 3) T2* or susceptibility-weighted imaging, 4) dynamic susceptibility contrast perfusion, 5) FLAIR with contrast injection, 6) T1 with contrast injection preferentially using the 3D spin echo images. The role of the nuclear medicine imaging is still limited in the diagnosis of brain metastasis. The Tc-sestamibi brain imaging or PET with amino acid tracers can differentiate local brain metastasis recurrence from radionecrosis but still to be evaluated.

5 Article Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? 2014

Baroudjian, Barouyr / Boussemart, Lise / Routier, Emilie / Dreno, Brigitte / Tao, Yungan / Deutsch, Eric / Blanchard, Pierre / Dhermain, Frédéric / Vilcot, Laurence / Vagner, Stephan / Eggermont, Alexander / Mateus, Christine / Robert, Caroline. ·Department of Medical Oncology. · Department of Medical Oncology,, INSERM U981. · Dermatology Clinic, Hôtel Dieu, Nantes, FRANCE. · Department of Radiation Oncology. · Department of Radiology, Institute Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif, FRANCE. · INSERM U981. ·Eur J Dermatol · Pubmed #24721778.

ABSTRACT: -- No abstract --